UroGen Pharma (URGN) Income towards Parent Company (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Income towards Parent Company data on file, last reported at -$23.6 million in Q1 2026.

• Quarterly Income towards Parent Company rose 46.23% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$97.9 million (up 8.6% YoY) and the FY2025 annual result came in at -$118.1 million, down 23.68% from the prior year.
• Income towards Parent Company fell to -$23.6 million in Q1 2026, from $9.0 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $9.0 million in Q4 2025 to a low of -$49.9 million in Q2 2025.
• A 5-year average of -$23.3 million and a median of -$25.8 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 1284.97% — and 2025, when it soared 246.34%.
• Tracing URGN's Income towards Parent Company over 5 years: stood at -$2.3 million in 2022, then soared by 122.89% to $519000.0 in 2023, then plunged by 1284.97% to -$6.1 million in 2024, then soared by 246.34% to $9.0 million in 2025, then slumped by 361.93% to -$23.6 million in 2026.
• The last three Income towards Parent Company figures came in at -$23.6 million (Q1 2026), $9.0 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.